C-myc Oncogene and Breast Cancer Prognosis
Author Information
Author(s): A.P. Locker, C.S. Dowle, I.O. Ellis, C.W. Elston, R.W. Blamey, K. Sikora, G. Evan, R.A. Robins
Primary Institution: Nottingham City Hospital
Hypothesis
Can c-myc oncoprotein levels in breast cancer predict patient survival and disease-free intervals?
Conclusion
High levels of c-myc oncoprotein are associated with well-differentiated breast tumors, but they do not predict patient survival or disease-free intervals.
Supporting Evidence
- High levels of c-myc oncoprotein were associated with well-differentiated tumors.
- There was no correlation between c-myc levels and patient survival.
- Low levels of c-myc oncoprotein were linked to poorly differentiated tumors.
Takeaway
This study looked at a protein called c-myc in breast cancer and found that while it can show how well the tumor is differentiated, it doesn't help predict how long a patient will live or stay cancer-free.
Methodology
Flow cytometric assay was used to measure c-myc oncoprotein levels in tumor samples from 141 patients.
Limitations
The study did not find significant associations between c-myc levels and patient survival or disease-free intervals.
Participant Demographics
All participants were operable breast cancer patients who underwent surgery between 1974 and 1976.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website